IN2012DN01269A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01269A
IN2012DN01269A IN1269DEN2012A IN2012DN01269A IN 2012DN01269 A IN2012DN01269 A IN 2012DN01269A IN 1269DEN2012 A IN1269DEN2012 A IN 1269DEN2012A IN 2012DN01269 A IN2012DN01269 A IN 2012DN01269A
Authority
IN
India
Prior art keywords
medicaments
variables
formula
disclosed
inhibitory activity
Prior art date
Application number
Inventor
Sangamesh Badiger
Murali Chebrolu
Mathias Frederiksen
Philipp Holzer
Konstanze Hurth
Lei Li
Hui Liu
Rainer Martin Lueoend
Rainer Machauer
Henrik Moebitz
Ulf Neumann
Rita Ramos
Heinrich Rueeger
Michael Schaefer
Marina Tintelnot-Blomley
Siem Jacob Veenstra
Markus Voegtle
Xin Xiong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45468934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN01269(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2010/060718 external-priority patent/WO2011009943A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2012DN01269A publication Critical patent/IN2012DN01269A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

Disclosed are oxazine derivatives of formula (I) having BACE inhibitory activity, wherein all of the variables are as defined in the specification, in free form or in salt form, their preparation methods, their medical use and medicaments comprising them.
IN1269DEN2012 2010-07-13 2011-07-13 IN2012DN01269A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36370210P 2010-07-13 2010-07-13
PCT/EP2010/060718 WO2011009943A1 (en) 2009-07-24 2010-07-23 Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders
US201161432058P 2011-01-12 2011-01-12
US201161435088P 2011-01-21 2011-01-21
PCT/CN2011/077119 WO2012006953A1 (en) 2010-07-13 2011-07-13 Oxazine derivatives and their use in the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
IN2012DN01269A true IN2012DN01269A (en) 2015-05-15

Family

ID=45468934

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1269DEN2012 IN2012DN01269A (en) 2010-07-13 2011-07-13

Country Status (31)

Country Link
US (2) US20120302558A1 (en)
EP (1) EP2483255B1 (en)
JP (1) JP5128019B1 (en)
KR (2) KR101391041B1 (en)
CN (1) CN102666507B (en)
AU (1) AU2011278825B2 (en)
BR (1) BR112012004154A2 (en)
CA (1) CA2771928C (en)
CO (1) CO6501189A2 (en)
DK (1) DK2483255T3 (en)
EA (1) EA020008B1 (en)
EC (1) ECSP12011692A (en)
ES (1) ES2442905T3 (en)
HK (1) HK1168091A1 (en)
HR (1) HRP20140011T1 (en)
IL (1) IL218034A0 (en)
IN (1) IN2012DN01269A (en)
MA (1) MA33509B1 (en)
MX (1) MX2012002439A (en)
MY (1) MY150939A (en)
NZ (1) NZ598137A (en)
PE (1) PE20121617A1 (en)
PL (1) PL2483255T3 (en)
PT (1) PT2483255E (en)
RS (1) RS53096B (en)
SG (1) SG178311A1 (en)
SI (1) SI2483255T1 (en)
TN (1) TN2012000067A1 (en)
TW (1) TWI421250B (en)
WO (1) WO2012006953A1 (en)
ZA (1) ZA201200880B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107723290A (en) * 2017-08-14 2018-02-23 蔡祥胜 One kind restructuring human oocyte's oolemma ZP3 albumen and preparation method thereof

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0617852A2 (en) 2005-10-25 2011-08-09 Shionogi & Co aminodihydrothiazine derivatives as well as compositions containing them
WO2008133273A1 (en) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Pharmaceutical composition for treatment of alzheimer's disease
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
WO2009151098A1 (en) 2008-06-13 2009-12-17 塩野義製薬株式会社 SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING β-SECRETASE-INHIBITING ACTIVITY
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-aminopyridin-4-one and 2-aminopyridine derivative both having bace1-inhibiting activity
PT2411395E (en) 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Furopyrimidinedione derivatives as trpa1 modulators
ES2456515T3 (en) 2009-03-23 2014-04-22 Glenmark Pharmaceuticals S.A. Fused pyrimidinedione derivatives as modulators of TRPA1
AR077328A1 (en) * 2009-07-24 2011-08-17 Novartis Ag DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
UA108363C2 (en) 2009-10-08 2015-04-27 IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
EP2485591B1 (en) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
RU2012129168A (en) 2009-12-11 2014-01-20 Сионоги Энд Ко. Лтд. OXASINE DERIVATIVES
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
AU2011321427A1 (en) 2010-10-29 2013-05-02 Shionogi & Co., Ltd. Naphthyridine derivative
JP2014505688A (en) * 2011-01-12 2014-03-06 ノバルティス アーゲー Oxazine derivatives and their use in the treatment of neurological disorders
US8524897B2 (en) * 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
PT2663561E (en) 2011-01-13 2016-06-07 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders
MX2013008192A (en) * 2011-01-13 2013-12-16 Novartis Ag Bace-2 inhibitors for the treatment of metabolic disorders.
US8815841B2 (en) * 2011-02-18 2014-08-26 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
JP2014514302A (en) 2011-04-13 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション 5-Substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions and their use
JPWO2012147763A1 (en) 2011-04-26 2014-07-28 塩野義製薬株式会社 Oxazine derivatives and BACE1 inhibitors containing the same
AU2012298983A1 (en) 2011-08-22 2014-02-27 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as BACE inhibitors, compositions and their use
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
WO2014059185A1 (en) 2012-10-12 2014-04-17 Amgen Inc. Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
AU2013363151A1 (en) 2012-12-20 2015-06-04 Merck Sharp & Dohme Corp. C5, C6 oxacyclic-fused iminothiazine dioxide compounds as BACE inhibitors
US9489376B2 (en) * 2013-01-02 2016-11-08 International Business Machines Corporation Identifying confidential data in a data item by comparing the data item to similar data items from alternative sources
CN105061305A (en) * 2015-08-31 2015-11-18 河南师范大学 Method for synthesizing 3-methylpyridine-2-carboxylic acid methyl ester in one step
CN112250580A (en) * 2020-10-28 2021-01-22 上海昂卓新材料科技有限公司 Preparation method of 2-nitro-2-substituted phenyl propane-1, 3-diol

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2005063738A1 (en) 2003-12-29 2005-07-14 Banyu Pharmaceutical Co.,Ltd Novel 2-heteroaryl-substituted benzimidazole derivative
TW200624426A (en) * 2004-09-21 2006-07-16 Lilly Co Eli BACE inhibitors
BRPI0617852A2 (en) 2005-10-25 2011-08-09 Shionogi & Co aminodihydrothiazine derivatives as well as compositions containing them
AU2008245082B8 (en) * 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
WO2008133273A1 (en) * 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Pharmaceutical composition for treatment of alzheimer's disease
GB0713686D0 (en) * 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-aminopyridin-4-one and 2-aminopyridine derivative both having bace1-inhibiting activity
AR077328A1 (en) * 2009-07-24 2011-08-17 Novartis Ag DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
US8188079B2 (en) * 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107723290A (en) * 2017-08-14 2018-02-23 蔡祥胜 One kind restructuring human oocyte's oolemma ZP3 albumen and preparation method thereof

Also Published As

Publication number Publication date
MA33509B1 (en) 2012-08-01
DK2483255T3 (en) 2014-01-20
TW201211038A (en) 2012-03-16
EP2483255A4 (en) 2013-01-09
CA2771928A1 (en) 2012-01-19
SG178311A1 (en) 2012-03-29
KR20120068839A (en) 2012-06-27
EA201200176A1 (en) 2012-09-28
KR101391041B1 (en) 2014-05-07
HRP20140011T1 (en) 2014-01-31
SI2483255T1 (en) 2014-02-28
WO2012006953A1 (en) 2012-01-19
JP2013508314A (en) 2013-03-07
NZ598137A (en) 2014-06-27
EP2483255A1 (en) 2012-08-08
KR101265451B1 (en) 2013-05-22
CN102666507B (en) 2014-09-17
ECSP12011692A (en) 2012-03-30
MY150939A (en) 2014-03-14
TWI421250B (en) 2014-01-01
BR112012004154A2 (en) 2017-05-30
AU2011278825B2 (en) 2012-09-20
PL2483255T3 (en) 2014-03-31
CN102666507A (en) 2012-09-12
ES2442905T3 (en) 2014-02-14
CO6501189A2 (en) 2012-08-15
US20120302558A1 (en) 2012-11-29
JP5128019B1 (en) 2013-01-23
MX2012002439A (en) 2012-04-10
KR20130016195A (en) 2013-02-14
EP2483255B1 (en) 2013-10-16
US20120172359A1 (en) 2012-07-05
EA020008B1 (en) 2014-07-30
IL218034A0 (en) 2012-04-30
PT2483255E (en) 2014-01-22
PE20121617A1 (en) 2012-12-14
HK1168091A1 (en) 2012-12-21
CA2771928C (en) 2013-08-06
RS53096B (en) 2014-06-30
ZA201200880B (en) 2012-08-29
TN2012000067A1 (en) 2013-09-19
AU2011278825A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
IN2012DN01269A (en)
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
MX343706B (en) Novel heterocyclic derivatives.
MX340533B (en) 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections.
MX336381B (en) Boronates as arginase inhibitors.
MX2012001070A (en) Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders.
MY158992A (en) Forms of rifaximin and uses thereof
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
NZ597517A (en) 5-fluoropyrimidinone derivatives
NZ709153A (en) Pyrimidinone derivatives having human neutrophil elastase inhibitory activity
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
PH12015501088A1 (en) Dimeric compounds
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
IN2015DN03998A (en)
PH12014502743A1 (en) Carbamate/urea derivatives
WO2013083975A3 (en) Novel pyrrole derivatives
PH12015500399A1 (en) Azaindolines
MX347620B (en) Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application.
MX2010002007A (en) Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors.
PH12015500185B1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
MX2013007055A (en) Sanglifehrin derivatives and methods for their production.
WO2014029888A3 (en) Branched or macrocyclic polyamines and uses thereof
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
MX2013009456A (en) Vinyl -aryl - sulfones for use in peritoneal carcinomatosis.
UA100955C2 (en) Oxazine derivatives and use thereof in the treatment of neural disorders